(Q42225514)

19 October 2017

title

Striking lack of T cell immunodominance in both a multiclade and monoclade HIV-1 epidemic: implications for vaccine development (English)

1 reference

19 October 2017

Wendy A Burgers

8

0 references

Eitel Mpoudi-Ngolé

7

object named as

Eitel Mpoudi-Ngole

1 reference

19 October 2017

5

Linda-Gail Bekker

1 reference

19 October 2017

Marcel Tongo

1

0 references

Carolyn Williamson

6

object named as

Carolyn Williamson

1 reference

19 October 2017

Lycias Zembe

2

1 reference

19 October 2017

Eugenie Ebong

3

1 reference

19 October 2017

Surita Roux

4

1 reference

19 October 2017

language of work or name

English

0 references

publication date

2 March 2014

1 reference

19 October 2017

1 reference

19 October 2017

volume

32

1 reference

19 October 2017

issue

20

1 reference

19 October 2017

page(s)

2328-2336

1 reference

T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Global trends in molecular epidemiology of HIV-1 during 2000-2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Evolutionary and immunological implications of contemporary HIV-1 variation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Higher cross-subtype IFN-γ ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Increased genetic diversity and intersubtype recombinants of HIV-1 in blood donors from urban Cameroon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Characterization of HIV-1 gag and nef in Cameroon: further evidence of extreme diversity at the origin of the HIV-1 group M epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

High HIV type 1 group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, Democratic Republic of the Congo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Drug resistance pattern of HIV type 1 isolates sampled in 2007 from therapy-naive pregnant women in North-Central Nigeria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Diversity is demonstrated in class I HLA-A and HLA-B alleles in cameroon, africa: Description of HLA-A*03012, *2612, *3006 and HLA-B*1403, *4016, *4703

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

HLA class I diversity among rural rainforest inhabitants in Cameroon: identification of A*2612-B*4407 haplotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Characterization of Gag and Nef-specific ELISpot-based CTL responses in HIV-1 infected Indian individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Lessons learned from HIV-1 vaccine trials: new priorities and directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Molecular epidemiology of HIV in two highly endemic areas of northeastern South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Genetic characterization of HIV before widespread testing of HIV vaccine candidates at a clinical trial site in Pretoria, South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

HIV-1 recombinants with multiple parental strains in low-prevalence, remote regions of Cameroon: evolutionary relics?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

A global approach to HIV-1 vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Immune control of HIV: the obstacles of HLA and viral diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Impact of MHC class I diversity on immune control of immunodeficiency virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Immune clearance of highly pathogenic SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.063

10.1016/J.VACCINE.2014.02.063

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference